© 1994 British Society for Rheumatology
research-article |
INTESTINAL PERMEABILITY IN PATIENTS WITH ANKYLOSING SPONDYLITIS AND THEIR HEALTHY RELATIVES
Department of Rheumatology and Internal Medicine Service, University of Granada Hospital E-18012 Spain
Correspondence to:
Correspondence to: O. Martínez-González, Avda. de Linares 14, Bl-2, 4°F, 23400-Ubeda (Jaén), Spain.
Patients with AS were previously found to have increased intestinal permeability using the 51Cr-EDTA resorption test In order to discover whether this alteration has taken place prior to, or as a consequence of the disease, we studied the intestinal permeability to 51Cr-EDTA in 20 patients with AS, 65 of their healthy relatives, and 25 normal volunteers. We also considered the HLA B27 antigen, the serum immunoglobulin A levels, the disease activity, the existence of peripheral arthritis, the ESR, the CRP values and the intake of drugs at the time of study. Gut permeability was found to have increased in the patients and their healthy relatives compared to the control group. No difference in gut permeability was found between patients and relatives regardless of whether they had the HLA B27 antigen or not. The increased intestinal permeability in the patients had no relation to the disease activity, to the presence of peripheral arthritis or to the intake of NSAIDs. Gut permeability was shown to bear no relation to IgA levels, ESR or CRP. Our findings suggest that the increase in gut permeability in AS patients and their relatives is a primary defect and may be an aetiologic factor in this disease.
KEY WORDS: Ankylosing spondylitis, Intestinal absorption, Intestinal diseases, Non-steroidal anti-inflammatory agents, Human, Family, Genetics, Relatives
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  A. Goebel, S. Buhner, R. Schedel, H. Lochs, and G. Sprotte Altered intestinal permeability in patients with primary fibromyalgia and in patients with complex regional pain syndrome Rheumatology, August 1, 2008; 47(8): 1223 - 1227. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S Generini, R Giacomelli, R Fedi, A Fulminis, A Pignone, G Frieri, A Del Rosso, A Viscido, B Galletti, M Fazzi, et al. Infliximab in spondyloarthropathy associated with Crohn's disease: an open study on the efficacy of inducing and maintaining remission of musculoskeletal and gut manifestations Ann Rheum Dis, December 1, 2004; 63(12): 1664 - 1669. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
I Fresko, V Hamuryudan, M Demir, N Hizli, H Sayman, M Melikoglu, R Tunç, S Yurdakul, and H Yazici Intestinal permeability in Behcet's syndrome Ann Rheum Dis, January 1, 2001; 60(1): 65 - 66. [Abstract] [Full Text]
|
|
|
|
|
|
D N. Leitch and J N Fordham Intestinal perforation in a patient with severe ankylosing spondylitis Ann Rheum Dis, August 1, 1997; 56(8): 458 - 460. [Full Text]
|
|